Related Concept Videos
Tumor Immunotherapy
Sustainable Development
Development of the Lymphatic System
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
Language Development
The critical period for language acquisition suggests that the ability to acquire language is at its peak early in life. As people age, this proficiency decreases. Language development begins very...
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Development of the Heart
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Cyano-modulated Zn(II)-Schiff base complexes for lysosome-targeted fluorescence imaging and pH-responsive camptothecin delivery.
Targeting the ELF1/EGFR/ERK positive feedback loop overcomes resistance to androgen receptor inhibition in AR-Vs positive prostate cancer.
Related Experiment Video
Updated: Feb 5, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
New developments in immunotherapy for lymphoma.
Benjamin Heyman1, Yiping Yang1,2
1Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine.
Immunotherapies for lymphoma, including CAR T-cells and bispecific antibodies, have revolutionized treatment. This review focuses on promising clinical developments and strategies for improving these advanced lymphoma therapies.
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Immunotherapy has transformed lymphoma treatment over the past decades.
- Rituximab marked a significant advancement as the first immunotherapy for B-cell non-Hodgkin lymphoma.
- Numerous novel immunotherapeutic strategies are now available for lymphoma care.
Purpose of the Study:
- To review promising immunotherapeutic approaches for lymphoma currently in clinical development.
- To focus on clinical trial data and strategies for enhancing treatment efficacy.
- To provide an overview of the evolving landscape of lymphoma immunotherapy.
Main Methods:
- Review of recent clinical trials and studies on novel immunotherapies for lymphoma.
- Analysis of key immunotherapeutic classes: CAR T-cells, bispecific antibodies, immune checkpoint inhibitors, and vaccines.
- Discussion of challenges and considerations for novel therapies, including timing, patient selection, duration, toxicity, and cost.
Main Results:
- Significant progress has been made in developing immunotherapies beyond rituximab.
- Chimeric antigen receptor T-cells, bispecific antibodies, immune checkpoint inhibitors, and vaccines show considerable promise.
- Ongoing research is refining patient selection, treatment protocols, and managing toxicity for these therapies.
Conclusions:
- The field of lymphoma immunotherapy is rapidly advancing with innovative approaches.
- Careful consideration of treatment parameters and patient factors is crucial for optimizing outcomes.
- Further research and clinical trials are essential to improve the effectiveness and accessibility of these life-saving treatments.

